KAZIA THERAPEUTICS LTD (KZIA) Form 424B5 — Aug 31, 2026
Kazia Therapeutics priced an underwritten public offering of 2,276,800 ADSs at $15.50 each plus pre-funded warrants on 303,200 ADSs, for gross proceeds of $39,989,969 and estimated net proceeds of about $37 million after $2,799,300 in underwriting discounts. Each unit includes Series A warrants on 2,243,478 ADSs at $17.825 and Series B warrants on 2,064,000 ADSs at $19.375, expiring on clinical milestones or five years; full exercise could add roughly $80 million more and lift ordinary shares outstanding from 6.48 billion to about 9.93 billion, roughly 53% above the pre-deal count.
Key figures
- Cash Position
- 49886158
- Gross Proceeds
- 39989969
- Offering Price
- 15.5
- Shares Offered
- 2276800
- Shares Outstanding
- 6,484,439,234 ordinary shares as of Aug 26, 2026; 7,774,439,234 expected post-closing; 9,928,178,234 fully as-adjusted if all warrants exercise
- Pro Forma Cash
- 87076827
- Orr Tnb Phase1b
- 83% (5 of 6 evaluable patients)
- Shelf Capacity
- 200000000
- Dilution Per Ads
- 10.69
- Series AWarrant Adss
- 2243478
- Series BWarrant Adss
- 2064000
- Discount To Last Close
- approximately 8%
- Estimated Net Proceeds
- $37 million
- Series AExercise Price
- 17.825
- Series BExercise Price
- 19.375
- Pre Funded Warrants Adss
- 303200
- Underwriting Discounts
- 2799300
- Potential Series AProceeds
- $40 million
- Potential Series BProceeds
- $40 million
- Clinical Benefit Tnb Phase1b
- 6 of 6 evaluable patients
- Ctc Cluster Median Reduction
- 83% (range 76-90%)
- Estimated Offering Expenses
- 600000
- Net Proceeds Before Expenses
- 37190669
- Pre Funded Warrant Exercise Price
- 0.0001
- Last Reported Sale Price Aug27 2026
- 16.9
Price after filing
Close on the filing date to close N calendar days later (from $13.77). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.